OLE molecule restores microglial function to combat Alzheimer's disease

Researchers have identified an experimental molecule named OLE that reactivates the brain’s immune cells to combat Alzheimer’s disease by reducing toxic beta-amyloid plaques and enhancing memory in animal models.

The study, published in Cell Death and Disease, was conducted by José Vicente Sánchez Mut at the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and Miguel Hernández University of Elche (UMH), collaborating with Johannes Gräff of the École Polytechnique Fédérale de Lausanne (EPFL).

How OLE Restores Microglial Protective Functions

Alzheimer’s disease is characterized by the accumulation of beta-amyloid plaques in the brain, which normally are cleared by microglia, specialized immune cells. However, during disease progression, microglia lose their protective abilities, allowing plaques to build up and damage neurons.

The researchers found that OLE, derived from the PM20D1 gene, shifts microglia back to a protective state. Treated microglia migrated toward beta-amyloid plaques and formed a barrier around them, limiting their harmful interaction with neurons and reducing plaque size and toxicity.

“One of the most significant findings is that we have identified a molecule capable of restoring microglia’s protective function,” stated Sánchez Mut, who leads the Functional Epi-Genomics of Aging and Alzheimer’s Disease laboratory at IN CSIC-UMH. He added that this reversal opens new therapeutic and research possibilities against Alzheimer’s disease.

OLE’s Effects Demonstrated in Animal Models

The team tested OLE in various experimental models. In genetically modified worms (C. elegans) that produce beta-amyloid, OLE treatment led to fewer protein aggregates and improved movement, indicating reduced disease-related damage.

In mouse models of Alzheimer’s disease, three months of OLE treatment resulted in improved memory performance and a decrease in beta-amyloid plaques in the brain.

Microglia Show Strongest Response to OLE

Single-cell analysis of brain cells revealed microglia as the most responsive to OLE treatment. These immune cells activated pathways for beta-amyloid clearance and regained their ability to migrate toward and encircle plaques.

Victoria Pozzi, first author of the study, explained, “Single-cell analysis allowed us to determine that microglia were the cells that responded most strongly to the treatment.” She noted that OLE enhanced microglial movement toward beta-amyloid plaques and improved their containment of disease-related damage.

Additional laboratory tests showed that OLE-treated microglia in cell cultures more effectively targeted beta-amyloid deposits. Furthermore, neuronal cultures exposed to Alzheimer’s-like stress exhibited increased survival when treated with OLE, suggesting potential direct neuroprotective effects.

Implications for Future Alzheimer’s Therapies

The findings emphasize OLE’s potential as a foundation for new Alzheimer’s treatments. The research is protected by two European patents, including one owned by CSIC, underscoring its translational and therapeutic promise.

The study titled “The PM20D1-OLE pathway induces microglia rewiring to ameliorate Alzheimer disease” was authored by Victoria Pozzi-Ruiz, Aida Giner de Gracia, Liliane Glauser, Mario Romani, Fatima Gunter-Rahman, Alejandro González-Ramón, Mahmood Haj-Yahya, Rajasekhar Kolla, Allison M. Burns, Hilal A. Lashuel, Johan Auwerx, Johannes Gräff, and Jose V. Sanchez-Mut. It was published on 27 April 2026 in Cell Death & Disease (DOI: 10.1038/s41419-026-08791-1).

The research received funding from Dementia Research Switzerland – Synapsis Foundation, the Pasqual Maragall Researchers Programme of the Pasqual Maragall Foundation, the Spanish Ministry of Science, Innovation and Universities, the Severo Ochoa Centres of Excellence programme of the State Research Agency (AEI), the Prometeo program of the Generalitat Valenciana, the European Regional Development Fund (ERDF), the CSIC Interdisciplinary Thematic Platform PTI+ NEURO-AGING, the Swiss National Science Foundation, EPFL, the European Research Council (ERC), the National Research Foundation of Korea (NRF), and the European Social Fund (ESF+).